ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program

25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is ...

Read more →

Government of Canada signs bilateral agreement with Quebec for Drugs for Rare Diseases

21 March 2025 - In Canada, one in 12 people live with a rare disease, and for most people affected, the ...

Read more →

Government of Canada signs Pharmacare agreement with Manitoba to improve affordable access to medications

27 February 2025 - Additional agreement will improve access and affordability of drugs for rare diseases. ...

Read more →

Drugs for rare diseases – Ontario agreement

24 January 2025 - Today, the Governments of Canada and the province of Ontario signed the National Strategy for Drugs ...

Read more →

Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases

5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...

Read more →

Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)

19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss ...

Read more →

NS parents dismayed by lack of access to new RSV vaccines for infants

3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...

Read more →

BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks

17 September 2024 -  BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, ...

Read more →

Abrysvo: Pfizer Canada's newly publicly funded vaccine a step towards national RSV prevention in older adults

19 September 2024 -  Today, Pfizer Canada announced that Abrysvo has been selected as the publicly funded vaccine for the ...

Read more →

Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Omvoh (mirikizumab) for adults with moderately to severely active ulcerative colitis

3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh ...

Read more →

First public drug plans provide reimbursement for Camzyos for adults with symptomatic obstructive hypertrophic cardiomyopathy

15 August 2024 - BMS Canada is pleased to announce an important milestone for eligible patients with symptomatic obstructive hypertrophic ...

Read more →

BC doctor calls on the province to cover obesity medications

17 July 2024 - A petition from Dr. Ali Zentner asking for more PharmaCare coverage has received almost 1,000 signatures. ...

Read more →

Bausch Health announces additional public drug plan listings for Uceris (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults

23 May 2024 - Bausch Health today announced additional Canadian public drug plan listings for Uceris (budesonide) aerosol foam to ...

Read more →

National pharmacare will reduce access to new medicines for 27 million privately insured Canadians

18 April 2024 - The federal Liberal-NDP coalition government recently announced it would work with the provinces to fund universal prescription ...

Read more →

Waiting for new medicines in Canada, Europe, and the United States: study finds Americans get better and faster access to innovative drugs

11 April 2024 - A recent study published by the Canadian Health Policy Institute examined the availability and wait times ...

Read more →